Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cutting-Edge Diagnostic Tool Rapidly Identifies Emerging SARS-CoV-2 Variants

By LabMedica International staff writers
Posted on 11 Nov 2024

As the COVID-19 pandemic continues to evolve, the emergence of new variants of the SARS-CoV-2 virus presents ongoing challenges for public health monitoring and response, despite the rise of vaccinations and herd immunity from previous infections, which have helped reduce severe cases compared to earlier in the pandemic. More...

While traditional methods, such as whole-genome sequencing (WGS), offer high accuracy, they are time-consuming and costly. Researchers have now made a significant advancement in the battle against COVID-19 by developing an innovative diagnostic tool that can quickly identify emerging variants of the SARS-CoV-2 virus. This new system combines advanced DNA detection technology with sophisticated computational algorithms to provide a faster and more affordable method for monitoring viral mutations, a crucial tool for managing future pandemics.

A team of researchers from Kumamoto University (Kumamoto, Japan) developed the novel diagnostic tool, Intelli-OVI, which integrates IntelliPlex micro-disc technology with a groundbreaking algorithm called Objective Variant Identification (OVI). This system offers a faster alternative for detecting and distinguishing over 20 SARS-CoV-2 variants with high accuracy. IntelliPlex technology uses a microdisc that is printed with a unique pictorial pattern (πCode), enabling the system to capture and analyze specific genetic mutations in the virus. This process allows the system to simultaneously handle multiple viral mutations, greatly accelerating detection. The OVI algorithm then interprets the data to identify both known and new variants by analyzing the unique mutation patterns.

In laboratory tests, Intelli-OVI successfully identified over 20 variants, including several subtypes of the Omicron variant, using 35 different DNA probes. Unlike traditional PCR-based methods, which can only detect a limited number of mutations, Intelli-OVI has the theoretical capacity to analyze up to 100 viral mutation sites at once, making it one of the most comprehensive diagnostic tools available. The successful development of Intelli-OVI holds the potential to make a significant contribution to global pandemic preparedness. The research team envisions that this technology could be applied to other rapidly evolving viruses, offering an essential tool for early detection and containment strategies.

"Our system can be easily updated to track new viral mutations," said Professor Yorifumi Satou, the lead researcher from the Joint Research Center for Human Retrovirus Infection (JRCHRI), Kumamoto University. "This new diagnostic tool has the potential to revolutionize how we monitor viral mutations, not just for COVID-19, but for future pandemics as well.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.